Publications by authors named "F Feroce"
Article Synopsis
- The study aims to determine factors that predict sensitivity to nivolumab in patients with metastatic renal cell carcinoma (mRCC) by analyzing immune cell profiles, specifically peripheral blood NK cells and regulatory T-cells (Tregs).
- A total of 57 mRCC patients and 62 healthy donors were analyzed for various immune cell characteristics over the first year of treatment, using statistical methods to identify key predictors.
- Results indicated that KIR2DL2/DL3+ NK cells and Helios+ Tregs at pretreatment serve as important predictors of nivolumab response, with specific thresholds related to overall survival (OS) and progression-free survival (PFS) showing their potential significance in treatment outcomes.
Article Synopsis
- CXCR4 plays a significant role in regulating the trafficking of T regulatory cells (Tregs), and the new antagonist R54 was tested on Tregs from renal cell carcinoma (RCC) patients.
- In the study, R54 was found to impair the function of peripheral blood Tregs, decreasing their frequency and secretion of inhibitory cytokines while increasing effector T cell secretion of IFN-γ.
- The results suggest that targeting CXCR4 with R54 could effectively inhibit Treg activity in the tumor microenvironment of RCC by affecting key signaling pathways and Treg characteristics.
Article Synopsis
- * Papillary and unclassified nccRCC subtypes show promising immunotherapy response rates of around 35%, while chromophobe cancers generally do not respond, and tumors with sarcomatoid features tend to respond well regardless of subtype.
- * There is a need for larger clinical trials focusing on nccRCC to better assess tumor response rates and evaluate biomarkers like PD-L1, which may indicate better treatment outcomes.
Background: The Italian Register of Actionable Mutations (RATIONAL) is a multicentric, observational study collecting next-generation sequencing (NGS)-based tumour profiling data of patients with advanced solid tumours.
Methods: The study enrols patients who had available an NGS-based tumour profiling (Pathway-A) or undergo comprehensive genomic profiling (CGP) with FoundationOne CDx assays within the trial (Pathway-B). The primary endpoint was the rate of actionable mutations identified.
Breast cancer is the most commonly diagnosed cancer and registers the highest number of deaths for women. Advances in diagnostic activities combined with large-scale screening policies have significantly lowered the mortality rates for breast cancer patients. However, the manual inspection of tissue slides by pathologists is cumbersome, time-consuming and is subject to significant inter- and intra-observer variability.
View Article and Find Full Text PDF